Vetr Inc. issued a report on Amgen, Inc. (NASDAQ:AMGN), raising its target price to $174.10 today
- Updated: March 19, 2017
Amgen, Inc. (NASDAQ:AMGN) had its target price raised to $174.10 by Vetr Inc. in a report released Monday March 20, 2017. The new target price indicates a possible upside of 0.03% based on the company's previous stock price.
On Monday March 13, 2017, Vetr Inc. released a statement on Amgen, Inc. (NASDAQ:AMGN) upped the target price from $0.00 to $174.10 that suggested a downside of -0.04%.
Displaying a price of $168.61, Amgen, Inc. (NASDAQ:AMGN) traded -6.38% lower on the day. The last stock close price is up 5.48% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.04% over the same period. AMGN has recorded a 50-day moving average of $171.88 and a 200-day moving average of $159.85. 23,936,848 shares of Amgen, Inc. traded, up from an avg. volume of 3,780,310
With a total market value of $0, Amgen, Inc. has P/E ratio of 16.47 with a 52 week low of $133.64 and a 52 week high of $184.21 .
In addition to Vetr Inc. reporting its target price, a total of 17 firms have reported on the stock. The consensus target price is $183.88 with 2 firms rating the stock a strong buy, 9 firms rating the stock a buy, 10 firms rating the stock a hold, zero equity analysts rating the company a underperform, and lastly zero equity analysts rating the company a sell.
Brief Synopsis About Amgen, Inc. (NASDAQ:AMGN)
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.